- $12.54m
- $10.17m
- $0.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.98 | ||
| Price to Tang. Book | 14.98 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 216.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -570.28% | ||
| Return on Equity | n/a | ||
| Operating Margin | -13794.83% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.14 | 1.01 | 1.35 | 0.48 | 0.06 | 0.05 | 0.05 | -39.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Directors
- Andrew Blank NEC (65)
- Peter Altman PRE (54)
- David McClung CFO (57)
- Edward Gillis SVP (59)
- Sujith Shetty OTH
- Jim Allen IND (65)
- Richard Krasno IND (79)
- Jay Moyes IND (67)
- Simon Stertzer IND (85)
- Krisztina Zsebo IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 12th, 1994
- Public Since
- November 13th, 1996
- No. of Shareholders
- 154
- No. of Employees
- 17
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 4,680,005
- Address
- 320 Soquel Way, SUNNYVALE, 94085
- Web
- https://www.biocardia.com/
- Phone
- +1 6502260123
- Auditors
- PKF San Diego,LLP
Upcoming Events for BCDA
BioCardia Inc Annual Shareholders Meeting
Q2 2025 BioCardia Inc Earnings Release
Similar to BCDA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the BioCardia share price?
As of Today at 19:35 UTC, shares in BioCardia are trading at $2.68. This share price information is delayed by 15 minutes.
How has the BioCardia share price performed this year?
Shares in BioCardia last closed at $2.68 and the price had moved by -52.36% over the past 365 days. In terms of relative price strength the BioCardia share price has underperformed the S&P500 Index by -57.04% over the past year.
What are the analyst and broker recommendations for BioCardia?
The overall consensus recommendation for BioCardia is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the BioCardia dividend yield?
BioCardia does not currently pay a dividend.
Does BioCardia pay a dividend?
BioCardia does not currently pay a dividend.
When does BioCardia next pay dividends?
BioCardia does not currently pay a dividend.
How do I buy BioCardia shares?
To buy shares in BioCardia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioCardia?
As of the previous close price of $2.68, shares in BioCardia had a market capitalisation of $12.54m.
Where are BioCardia shares listed?
Here are the trading details for BioCardia:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BCDA
What kind of share is BioCardia?
Based on an overall assessment of its quality, value and momentum BioCardia is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioCardia share price forecast for 2025?
The analyst consensus target price for shares in BioCardia is $15.50. That is 478.36% above the last closing price of $2.68.
Analysts covering BioCardia currently have a consensus Earnings Per Share (EPS) forecast of -$1.11 for the next financial year.
Find out moreWhat is the trend in the BioCardia share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioCardia. Over the past six months, its share price has outperformed the S&P500 Index by +12.65%.
As of the last closing price of $2.68, shares in BioCardia were trading +8.33% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioCardia PE Ratio?
The BioCardia PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.68.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioCardia?
BioCardia's management team is headed by:
- Andrew Blank - NEC
- Peter Altman - PRE
- David McClung - CFO
- Edward Gillis - SVP
- Sujith Shetty - OTH
- Jim Allen - IND
- Richard Krasno - IND
- Jay Moyes - IND
- Simon Stertzer - IND
- Krisztina Zsebo - IND